Standout Papers

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer 2014 2026 2018 2022 1.8k
  1. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer (2014)
    Thomas Powles, Joseph P. Eder et al. Nature
  2. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma (2020)
    Bruno Sangro, Ignacio Melero et al. Journal of Hepatology

Immediate Impact

15 by Nobel laureates 13 from Science/Nature 62 standout
Sub-graph 1 of 20

Citing Papers

A pan-cancer single-cell panorama of human natural killer cells
2023 Standout
Current best practice for bladder cancer: a narrative review of diagnostics and treatments
2022 Standout
1 intermediate paper

Works of Zachary Boyd being referenced

Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
2020 Standout
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
2014 StandoutNature
and 1 more

Author Peers

Author Last Decade Papers Cites
Zachary Boyd 2300 639 696 1167 1047 24 3.6k
Alexandre Calon 2617 493 249 981 1582 23 3.9k
Daniela Bruni 2663 917 286 2085 1167 13 4.3k
Daniele V. F. Tauriello 2954 552 263 1143 2199 33 4.7k
Christian Stockmann 1645 594 385 2227 1980 35 5.2k
Jake S. O’Donnell 2020 643 286 1390 863 17 3.0k
Shijun Kang 1964 836 249 1159 855 22 2.9k
Yoshinori Ino 1302 360 360 652 1672 63 3.4k
Andrew Sullivan 1501 496 408 504 1172 21 3.3k
Janice M. Mehnert 2368 750 373 929 848 62 3.5k
Shao‐Lai Zhou 1360 530 497 1157 1519 58 3.6k

All Works

Loading papers...

Rankless by CCL
2026